%0 Journal Article %T VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer %A Zhi, Xiuyi %A Gao, Wen %A Han, Baohui %A Yang, Yue %A Li, Hui %A Liu, Deruo %A Wang, Changli %A Min, Gong %A Long, Hao %A Rigas, James R. %A Carey, Mark %A Jahan, Thierry %A Sammann, Amanda %A Reza, Joseph %A Wang, Daoyuan %A Mann, Michael J. %A Jablons, David M. %A He, Jianxing %A Trials Consortium, for the China Clinical %J Journal of Thoracic Disease %D 2013 %B 2013 %9 %! VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer %K %X Background: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with non-small cell lung cancer (NSCLC). Methods: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. The primary endpoint of the study was safety, as reflected by a febrile neutropenia rate of <10%. Other endpoints assessed protocol compliance and the impact of minimally invasive surgical technique. Results: Patient accrual was completed at 1 center in the US and 10 centers in China in <6 months. Febrile neutropenia complicated treatment in 12 patients (9.0%), below the predetermined safety threshold of 14 patients. Four VATS and 8 open thoracotomy patients experienced febrile neutropenia (P=0.26). Completion of the three-cycle adjuvant regimen was achieved in 86% (95% CI, 77-95%) of patients. Sixty-two of 66 VATS patients compared to 53 of 67 open thoracotomy patients received all three doses according to protocol (P<0.01). Thirteen serious adverse events (9.8%) and no deaths were attributed to the study regimen. Conclusions: In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. Adjuvant treatment compliance was higher among patients undergoing a minimally invasive surgical approach. (ClinicalTrials.gov number NCT00883675) %U https://jtd.amegroups.org/article/view/1540 %V 5 %N 5 %P 578-584 %@ 2077-6624